BioSpace News Archive

Palisade Bio, Inc. today provides a business update and releases its financial results for the second quarter ending June 30, 2021.

180 Life Sciences Corp. announced the closing of its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock at a combined purchase price of $6.00 per share and accompanying warrant.

MicroQuin Ltd, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the potential of MicroQuin therapeutics (MQPs) and move them towards clinical trials as treatments for of a range of viruses including influenza, SARS-CoV-2, respiratory syncytial virus (RSV) and adenovirus.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

The allergy care market may bring good growth opportunities across the forecast period of 2019-2028.

Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to offer the first decentralized HRD (Homologous recombination deficiency) analytics solution in Latin America.